Fremanezumab (TEV-48125) is a humanised monoclonal antibody targeting CGRP, capable of neutralising human (IC50=7.94 nM), mouse (IC50=19.6 nM) and rat CGRP, and is indicated for the prevention of migraine. Fremanezumab inhibits CGRPs vasodilatory effects in the basilar artery constriction segment and suppresses activation of A-delta and high-threshold (HT) neurons in the meningeal nociceptive system triggered by cortical spreading depression (CSD) in rats. In vitro, Fremanezumab counteracts CGRPs immunosuppressive effects on microglia and lymphocytes.
Reinheit:
95.00%
CAS Nummer:
[1655501-53-3]
Target-Kategorie:
CGRP Receptor
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
